Renova Therapeutics Announces Strategic Focus and Roadmap Prioritization for Its Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus
Renova Therapeutics Appoints Dr. Vijay Mahant as CEO
RENOVA THERAPEUTICS ANNOUNCES AN ABSTRACT TO BE PRESENTED AT THE LATE-BREAKING SCIENTIFIC SESSION OF 2018 AMERICAN DIABETES ASSOCIATION MEETING: UROCORTIN-2 GENE TRANSFER EFFECTIVELY TREATS TYPE 1 DIABETES
ACC: BASIC TO TRANSLATIONAL SCIENCE PUBLISHES ARTICLE COMPARING EFFECTS OF UROCORTIN 2 VERSUS UROCORTIN 3 GENE TRANSFER ON LEFT VENTRICULAR FUNCTION AND GLUCOSE DISPOSAL
Renova Therapeutics Names New CFO
Worldwide Clinical Trials to support Ph III trial for Renova Therapeutics
RENOVA THERAPEUTICS ANNOUNCES ISSUANCE OF PATENT COVERING DELIVERY AND EXPRESSION OF PARACRINE GENES
New gene therapy improves insulin sensitivity and diabetes markers in mice
Gene Therapy: A New Twist on an Old Helix
Big Pharma Execs Join Renova Leadership Team
Patent Issued for Peptides in Diabetes Gene Therapy
Renova takes over Janssen's rights to heart failure candidate stresscopin
Stanford, Renova deal
Phase 3 trial of gene transfer therapy for patients with HF to launch
In the clinic: Renova Therapeutics end-of-phase 2 FDA meeting
Gene Therapy for Type 2 Diabetes Improves Insulin Sensitivity in Mice
Is It A Buyer's Market For Private Biotech Deals?
Renova Therapeutics to begin in-human trials of RT-200 gene transfer therapy for type 2 diabetes
Therapeutics: Urocortin 2 (UCN2)
Clayton Foundation for Research, Renova Therapeutics deal
News to note: Renova Therapeutics patent license
Encoding Glucose Control
Gene Transfer for Heart Failure Shows Promise
Intracoronary Gene Transfer Improved Ejection Fraction in Heart Failure
Gene Therapy Shows Potential In Treating Heart Failure
Left Ventricular Function in Heart Failure Improved Through Gene Transfer
Gene transfer therapy appears to benefit patients with HF
Renova raising funds for pivotal gene therapy trials
Gene Therapy Shows Early Promise Against Heart Failure
Gene transfer shows promise for treating heart failure
Herzinsuffizienz: Gentransfer über die Koronarien verbessert Pumpfunktion
Gene Transfer Shows Promise in Heart Failure Trial: Infusions Increase Heart Function beyond Optimal Therapy
Glimmer of hope found in treating heart failure with gene transfer
Promising Gene Therapy for Heart Failure
Gene transfer shows promise for treating heart failure
West Coast Biotech Roundup: Alfred Mann, ResMed, Illumina, & More [Renova Therapeutics mentioned]
Renova Therapeutics Awarded Additional NIH Funding to Continue Paracrine Gene Therapy Research
Lonza to make heart failure gene therapy for Renova at Houston site
Biotech Showcase™ 2016: Interview: Renova develops gene therapies for CHF and type 2 diabetes
Lonza and Renova Therapeutics Announce Manufacturing Agreement for Clinical Supply of RT-100 Gene Therapy
12 San Diego Life Sciences Startups to Watch in 2016
W&J to honor Entrepreneurs of the Year at Entrepreneurial Leadership Dinner
Renova Therapeutics Names Richard McCloskey Executive VP of Clinical Development
Genes and the Heart: How do you price a cure?
Video: Phase 2 Trial Results of Single-dose Gene Therapy for HF
Q&A With Jack Reich From Renova Therapeutics: Gene Therapy for Congestive Heart Failure Shows Promise in Early Trials
Promising Results on Gene Therapy for Congestive Heart Failure
Renova’s Gene Therapy To Reverse Heart Remodeling In CHF
Renova Therapeutics Announces Potential Expansion of Gene Therapy Platform for Heart Failure, Diabetes and Related Conditions
Renova Therapeutics Announces Strategic Focus and Roadmap Prioritization for Its Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus
Renova Therapeutics Announces an Abstract to be Presented at the Late-Breaking Scientific Session of 2018 American Diabetes Association Meeting: Urocortin-2 Gene Transfer Effectively Treats Type 1 Diabetes
JACC: Basic to Translational Science publishes article comparing effects of urocortin 2 versus urocortin 3 gene transfer on left ventricular function and glucose disposal
Renova Therapeutics announces issuance of patent covering delivery and expression of paracrine genes
Renova Therapeutics to present key components of FLOURISH gene therapy trial for the treatment of heart failure at Keystone Symposium
US FDA grants Fast Track designation to Renova Therapeutics RT-100 AC6 gene transfer for the treatment of heart failure.
Genetic Rx panel on gene therapy regulatory strategies led by Renova Therapeutics CEO and Co-founder
2017 Cell & Gene Meeting on the Mesa featuring Renova Therapeutics CEO & Co-founder as speaker
Renova Therapeutics leadership speaking at Cell & Gene Therapy CEO forum and Boulder Peptide Symposium
Renova Therapeutics co-founder awarded highest research honor by the U.S. Department of Veterans Affairs
'PLOS ONE' publishes results of cardiac-directed catalytically inactive AC6 in mice after sustained β-adrenergic stimulation
Urocortin 2 gene transfer increases glucose disposal and insulin sensitivity in type 2 diabetes
Industry leaders join Renova Therapeutics to lead preclinical programs into clinical development
'Human Gene Therapy' publishes review of randomized clinical trials of gene transfer for heart failure with reduced ejection fraction
UNIAPAC FOUNDATION THINK TANK IN PARIS SELECTS RENOVA THERAPEUTICS CEO AND CO-FOUNDER AS KEYNOTE SPEAKER FOR ANNUAL MEETING
CEO AND CO-FOUNDER OF RENOVA THERAPEUTICS TO PRESENT AT NOVEL CARDIOVASCULAR THERAPEUTICS SUMMIT
U.S. PATENT FOR UROCORTIN 2 GENE CONSTRUCTS ISSUED
RENOVA THERAPEUTICS ENTERS INTO AGREEMENT TO RECEIVE STRESSCOPIN INVESTIGATIONAL NEW DRUG FILE FROM JANSSEN
Renova Therapeutics selects Worldwide Clinical Trials as its Clinical Research Organization for Phase 3 trial of RT-100 AC6 gene transfer
Renova Therapeutics secures novel AAV vector license for use in metabolic and cardiovascular gene therapy development
Biotech finance expert joins Renova Therapeutics as CFO
Genetic Rx panel on gene therapy to feature Renova Therapeutics CEO and Co-founder
Renova Therapeutics announces successful End-of-Phase 2 meeting with FDA for RT-100 AC6 gene transfer therapy
Renova Therapeutics strengthens gene therapy IP estate with latest patent license
Renova Therapeutics to present on advancing gene therapy for chronic diseases at 18th annual BioJapan conference
JCI Insight publishes preclinical results of urocortin 2 gene transfer in mouse models of insulin resistance
Development-stage biotech Renova Therapeutics partners with NASDAQ Private Market
Renova Therapeutics selected to present at Cavendish Global Health Impact Forum at Biocom
Renova Therapeutics expands clinical development team with latest hire
JAMA Cardiology publishes Phase 2 results of AC6 gene transfer in patients with heart failure
Renova Therapeutics receives additional NIH grant to continue paracrine gene therapy research for congestive heart failure
Renova Therapeutics announces Delaware reincorporation
Lonza and Renova Therapeutics Announce Manufacturing Agreement for Clinical Supply of RT-100 Gene Therapy
CEO and Co-Founder of Renova Therapeutics receives Entrepreneur of the Year award from Washington & Jefferson College
Renova Therapeutics appoints Dr. Richard ‘Mac’ McCloskey to head company’s clinical development efforts
Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments
ESC 2015: Phase 2 data results to be revealed for first-in-class, single-dose gene therapy for congestive heart failure
RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate
Renova Therapeutics recruits seasoned expert to lead company’s regulatory and quality efforts
Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round
Cases of heart failure continue to rise; poorest people worst affected
Will Cell and Gene Therapies Reach a Tipping Point?
Heart Disease Is a Major Killer If You Have Diabetes
47% in China Likely Have Prediabetes Or Diabetes
Increase in Diabetes Cases Among Young People
Diabetes is even deadlier than we thought, study suggests
Heart failure projected to increase dramatically, according to new statistics
U.S. diabetics have worsening blood sugar control
Type 2 Diabetes - The Rising Silent Epidemic
8 Things I Didn’t Know About Heart Failure Until It Happened to Me
Common medications can make heart failure worse
Annual Decline in Heart-Disease Death Rates in U.S. Flat Since 2011
The Real Monthly Costs of Heart Failure
Self-care does not improve mortality in chronic heart failure patients
FDA Sees Spike in Gene and Cell Therapy Applications
Heart Failure Is the “Cancer” of Cardiovascular Disease
Medical forecast: Gene therapy, health information technology boom
Heart Failure Mortality Taking a Turn for the Worse: Heart failure death rates rising again after decade of decline
What is gene therapy?
Timeline: Milestones in gene therapy
More People Dying of Heart Disease, Stroke Worldwide: Study
4 Things to Know About Gene Therapy
Former NBA player Anthony Mason dies at age of 48
Borrowing for the Cure: Debt Financing of Breakthrough Treatments
Only Some Chronic Diseases Benefit from Disease Management Program
Scientists tease out genetic mutations linked to heart failure
NIH researchers tackle thorny side of gene therapy
Download our logo files, company snapshot and RT-100 fact sheet here. For our RT-100 video, please contact [email protected].
Cardiac-directed expression of a catalytically inactive adenylyl cyclase 6 protects the heart from sustained β-adrenergic stimulation
Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction
One-time injection of AAV8 encoding urocortin 2 provides long-term resolution of insulin resistance
Urocortin 3 Gene Transfer Increases LV Peak -dP/dt in Normal Mice
Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure
Intravenous AAV8 Encoding Urocortin-2 Increases Function of the Failing Heart in Mice
Unanticipated signaling events associated with cardiac adenylyl cyclase gene transfer
Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity
Increased regional function and perfusion after intracoronary delivery of adenovirus encoding fibroblast growth factor 4: report of preclinical data
Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart
Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris
Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus
Adenylyl cyclase and G protein receptor kinase expression during development of heart failure
Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice
Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy
Adenylyl cyclase increases survival in cardiomyopathy
Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function
Increased expression of adenylylcyclase type VI proportionately increases beta-adrenergic receptor-stimulated production of cAMP in neonatal rat cardiac myocytes
A beneficial role of cardiac P2X4 receptors in heart failure: rescue of the calsequestrin overexpression model of cardiomyopathy
Adenylyl cyclase type VI gene transfer reduces phospholamban expression in cardiac myocytes via activating transcription factor 3
Activation of PH-domain leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac myocytes expressing adenylyl cyclase type 6
Adenylyl cyclase type V deletion increases basal left ventricular function and reduces left ventricular contractile responsiveness to beta-adrenergic stimulation
Adenylyl cyclase type 6 deletion decreases left ventricular function via impaired calcium handling
Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure
Activation of Cardiac Adenylyl Cyclase Expression Increases Function of the Failing Ischemic Heart in Mice
Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction
Nitroprusside increases gene transfer associated with intracoronary delivery of adenovirus
Indirect intracoronary delivery of adenovirus encoding adenylyl cyclase increases left ventricular contractile function in mice
Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus
Signal peptide increases the efficacy of angiogenic gene transfer for treatment of myocardial ischemia